Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news


From To
Gilead Ignored HIV Groups Before Failed Bid To Have PrEP Subsidised In Australia

A drug manufacturer failed to take the advice of top HIV/AIDS organisations when it made a submission for a highly effective HIV prevention drug to be subsidised by the government, those organisations say.

25 August 2016
German medicines watchdog rejects ‘new tenofovir’ pill

The German health technology assessment agency IQWiG has announced that it finds no advantage in Descovy, a combination pill containing a new version of the HIV

22 August 2016
Gus Cairns
Hillary Clinton calls out drug maker Gilead over price of hepatitis C pills

Democratic presidential nominee Hillary Clinton said Wednesday her administration will go after drug companies that charge exorbitant prices, singling out the company Gilead, whose hepatitis C drugs cost between $900 and $1,000 per pill in the United States.

19 August 2016
German agency criticises European programme for speeding some drug approvals

In pointed remarks, Germany’s cost-effectiveness watchdog has criticised an effort by European regulators to accelerate approval for new medicines by limiting its requirements for evidence. The concerns raised by the agency come as regulators on both side of the Atlantic increasingly look to such approaches to get new drugs to patients with unmet medical needs. At issue is a proposal called adaptive pathways, a term used to describe a method for jumpstarting drug approvals for select patient populations. Two years ago,an EMA pilot programme was launched to compare initial data used for approval with so-called “real world” data, which is subsequently gathered after the medicines are in use.

18 August 2016
Cancer drug companies cut prices to win NHS approval

Tougher new policy by regulator means pharma firms are having to offer better value for money to get treatments accepted by NHS.

18 August 2016
The Guardian
ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment

The phase III programme comprises two identical studies (GEMINI 1 and 2) comparing a two-drug regimen of dolutegravir plus lamivudine with a three-drug regimen of dolutegravir plus the fixed-dose tablet tenofovir/emtricitabine (Truvada®), as treatment for HIV-1 infection in adults who have not received prior antiretroviral therapy.

16 August 2016
ViiV press release
Gilead bags Genmab tech to develop bispecific antibody against HIV

Gilead has struck a deal to access bispecific antibody technology from Genmab. The agreement gives Gilead an exclusive license to use the Danish drugmaker’s bispecific platform to create an HIV therapeutic, plus an option to take up another exclusive license on the technology.

12 August 2016
As EU Approval Moves Closer Are Governments Prepared For PrEP?

On Friday the EU's Committee for Medicinal Products for Human Use (CHMP) announced its positive opinion on Gilead’s HIV pre-exposure prophylaxis product Truvada PrEP. But with many European governments trying to control healthcare costs, the biggest issue facing Truvada PrEP might not be approval but rather reimbursement.

27 July 2016
Seeking Alpha
South Africa: Produce HIV Drugs Locally, Says Science Minister

Durban -South Africa should advocate for the creation of local HIV drug manufacturing companies and stop depending on foreign pharmaceutical multinationals for these drugs, says Science and Technology Minister Naledi Pandor.

22 July 2016
HIV Drug Pricing Protest Interrupts PrEP Session at AIDS 2016

Protesters against the high cost of antiretroviral drugs joined forces and marched together today, interrupting a research presentation today at the 21st International AIDS Conference (AIDS 2016).

21 July 2016
BETA blog
← First12345...89Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap